4.7 Article

Allosteric modulation of sigma receptors by BH3 mimetics ABT-737, ABT-263 (Navitoclax) and ABT-199 (Venetoclax)

期刊

PHARMACOLOGICAL RESEARCH
卷 142, 期 -, 页码 87-100

出版社

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.phrs.2019.01.040

关键词

Sigma receptor; BH3 mimetic; Allosteric modulator; ABT-737; ABT-263; ABT-199

资金

  1. University of Missouri Life Sciences Mission Enhancement Program
  2. Harry S. Truman Memorial Veterans' Hospital

向作者/读者索取更多资源

ABT-737, ABT-263 (Navitoclax) and ABT-199 (Venetoclax) are under intensive preclinical and clinical investigation as treatments for hematologic and other malignancies. These small molecules mimic pro-death B-cell lymphoma-2 (Bcl-2) Homology 3 (BH3) domain-only proteins. They also bear a structural resemblance to certain sigma (sigma) receptor ligands. Moreover, the Bcl-2 and a receptor protein families are both located primarily at the endoplasmic reticulum, mediate cell death and survival through protein-protein interactions, and physically associate. Accordingly, we examined the ability of the ABT series of BH3 mimetics to interact with sigma receptors using radioligand-binding techniques. Negative allosteric modulation of [H-3](+)-pentazocine, an agonist, binding to al receptors in guinea pig brain membranes was observed for ABT-737, ABT-263 and ABT-199. Findings included reduction of specific binding to distinct plateaus in concentration-dependent fashion, significant slowing of radioligand dissociation kinetics, and decreases in radioligand affinity with no or modest changes in maximal receptor densities. Using a ternary complex model, dissociation constants (K-X) for modulator binding to the sigma 1 receptor ranted from 1 to 2.5 mu M, while negative cooperativity factors (alpha), representing the changes in affinity of ligand and modulator when bound as a ternary complex with the receptor, ranged from 0.15 to 0.42. These observations were extended and reinforced by studies using intact small cell (NCI-H69) and non-small cell (NCI-H23) lung cancer cells, and by using an antagonist sigma 1 receptor radioligand, E-N-1-(3'-[I-125] iodoallyl)-N'-4-(3 '',4 ''-dimethoxyphenethyl)piperazine, in mouse brain membranes. By contrast, exploratory studies indicate marked enhancement of the a2 receptor binding of [H-3]1,3-di-(o-tolyl)guanidine/(+)-pentazocine in NCI-H23 cells and guinea pig brain membranes. These findings raise intriguing questions regarding mechanism and potential functional outcomes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据